Review decision date: July 2014
We checked this guideline and decided that it should be updated. For details, see the update decision and the process for deciding if an update is needed. Details of the update have been published on this page. This guideline will be checked again for update at its scheduled time point according to the methods described in the guidelines manual.
Next review date: June 2016
This clinical guideline offers evidence-based advice on the effective management of lower urinary tract symptoms (LUTS) in men. The lower urinary tract consists of the bladder, prostate gland and urethra (the tube that carries urine from the bladder to the end of the penis).
This guideline was previously called lower urinary tract symptoms: the management of lower urinary tract symptoms in men.
A recommendation on phosphodiesterase-5 inhibitors has been added to section 1.4 on drug treatment. A research recommendation on phosphodiesterase-5 inhibitors has been added to section 2.5. The addendum contains details of the methods and evidence used to develop these recommendations.
This guideline updates and replaces:
- Interventional procedure guidance 15
- Interventional procedure guidance 120
- Interventional procedure guidance 224
- Interventional procedure guidance 256